Accelerator Corp., a Seattle-based life sciences investment fund, is making some big changes. The firm announced two additions to its leadership team and also changed its name to Accelerator Life Science Partners.
One of the new additions is former Juno Therapeutics executive Kendall Mohler, who will serve in the new role of chief development officer. Mohler is a biotech and pharmaceutical veteran, who joined Juno in 2013 and served as its chief science officer and later its VP of research. According to his LinkedIn page, he retired from that work earlier this year.
The second addition is longtime biotech finance executive Ian Howes, who will serve as the company’s CFO. Howes has served as a biotech CFO in startups and established companies for the past 26 years, most recently at North Carolina’s Heart Metabolics.
“We believe that fostering innovation requires more than providing capital and lab space. It also requires a shared passion for advancing human health and an understanding of how to navigate the complex landscape that such advances often require,” Accelerator CEO Thong Q. Le said in a press release. “The additions of Ken and Ian to our executive team enhances our ability to make that journey — for the benefit of our investors, our portfolio companies and the talented entrepreneurs we work with, and ultimately for patients in need.”
Accelerator’s investors include venture partners and national life science companies, including ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation and Pfizer Venture Investments. It has funded 19 companies with $130 million so far, including a $62.8 million fund in 2015.
The fund invests in biotech startups, including two in Seattle: Rodeo Therapeutics and Apogen Biotechnologies.